Lumos Pharma, Inc.
Records under this name other than the patents Lumos Pharma, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 12 patents it holds.
Showing 1 to 7 of 7 · Back to Lumos Pharma, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,493,062 | Synthesis of cyclocreatine and analogs thereof Lapsed on the fee record Ended Dec 3, 2023 · From the USPTO record | Lapsed on the fee record | Ended Dec 3, 2023 | From the USPTO record |
| US 7,998,486 | Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes Lapsed on the fee record Ended Aug 16, 2023 · From the USPTO record | Lapsed on the fee record | Ended Aug 16, 2023 | From the USPTO record |
| US 10,377,721 | Synthesis of cyclocreatine and analogs thereof Lapsed on the fee record Ended Aug 13, 2023 · From the USPTO record | Lapsed on the fee record | Ended Aug 13, 2023 | From the USPTO record |
| US 8,916,169 | Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes Lapsed on the fee record Ended Dec 23, 2022 · From the USPTO record | Lapsed on the fee record | Ended Dec 23, 2022 | From the USPTO record |
| US 10,081,605 | Synthesis of cyclocreatine and analogs thereof Lapsed on the fee record Ended Sep 25, 2022 · From the USPTO record | Lapsed on the fee record | Ended Sep 25, 2022 | From the USPTO record |
| US 8,357,777 | Enhanced immunogenicity of tumor associated antigens by addition of αgal epitopes Lapsed on the fee record Ended Jan 22, 2021 · From the USPTO record | Lapsed on the fee record | Ended Jan 22, 2021 | From the USPTO record |
| US 9,512,158 | Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes Lapsed on the fee record Ended Dec 6, 2020 · From the USPTO record | Lapsed on the fee record | Ended Dec 6, 2020 | From the USPTO record |